Skip to content

EXOZ EXOZ Equity Method Investments

Equity Method Investments at other companies

Ginkgo Bioworks logo
Ginkgo BioworksDNA
$13.31M
Opko Health logo
Opko HealthOPK
$10.53M-17.4%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$209.2M-1.3%

Other financials

Income statement

See full
Revenue$17.5K
Operating income-$2.4M-22.4%
Net income-$2.4M-27.7%
EPS (diluted)-$0.28-27.3%

Balance sheet

See full
Cash & equivalents$1.4M-83.0%
Total debt$1.2M-8.8%
Total equity$1.5M-82.8%
Total assets$4.0M-65.1%

Cash flow

See full
Operating cash flow-$1.5M-34.5%
CapEx$57.6K+85.5%
Free cash flow-$1.6M-35.8%

Valuation

See full
Market cap$76.8M-5.6%
Enterprise value$76.57M+1.0%
P/S1,096.1×

Profitability

See full
Operating margin-14,489.6%
Net margin-2,909.1%
FCF margin-10,117.8%

Returns & leverage

See full
Return on equity-185.8%
Debt / equity0.8×+0.6×
Current ratio1.3×-5.2×

Where this comes from

Reported directly by EXOZ in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInvestments.

The official record: EXOZ’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about EXOZ's equity method investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EXOZ's equity method investments?
EXOZ (EXOZ) reported equity method investments of $43.44K in Q4 2025.
What is the long-term trend for EXOZ's equity method investments?
Over 2 years (2023 to 2025), EXOZ's equity method investments has grown at a 1.7% compound annual growth rate (CAGR), from $42K to $43.44K.
What does equity method investments mean?
Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.